Lilly Pays KeyBioscience $55m Up Front to Expand Its Early Diabetes Pipeline
Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.
You may also be interested in...
External innovation directly links to commercial success for big pharma, and will continue to do so until 2026, according to a new report by Datamonitor Healthcare.
Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.